Emblem Corp. (“Emblem” or the “Company”) (TSXV:EMC), a vertically integrated cannabis company focused on research, development, production and distribution of cannabis products for medical purposes, announced today its growth plans for 2018.
Incoming President and CEO, Nick Dean, who brings years of consumer marketing, retail and leadership experience to Emblem’s dedicated team, will be moving forward under a new paradigm focused on building capacity to meet the expected surge in demand, ramping up patient acquisition on the medical cannabis market, and embarking on a number of strategic partnerships that will position it well for the adult-use cannabis market.
“We will be entering a new era when Canada finally removes the stigma and legalizes adult-use cannabis,” noted Dean. “We intend on leveraging our award-winning customer experience, our significant strengths in the medical segment and our dedicated focus on providing the highest quality products to become a major player in the recreational segment as well.”
Emblem currently has over 8,500 square feet of flowering capacity at its closed box facility in Paris, Ontario. The Company’s recent major land acquisition will soon pave the way for state-of-the-art greenhouse facilities that will significantly expand the Company’s total production capacity to upwards of 17,000 kilograms of dried flower per annum.
“With our oils license now in place and the adult-use market on the horizon, we are looking to significantly increase our cultivation capacity, while at the same time maintaining our commitment to produce high-quality product at low cost,” says Dean. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic transactions and other opportunities to accelerate our growth objectives in Canada and international markets.”
Emblem remains focused on the production of the highest quality cannabis flower and derivative products through a multi-pronged approach of “closed box” and “greenhouse” production facilities. The Company views having parallel paths and the optionality of both types of cultivation facilities available as a prudent approach to maximizing return on capital employed.
Source: Technical 420